Print

Virogen, Inc. Receives Purchase Orders Totaling $400,000  
11/6/2008 9:05:47 AM

MINNEAPOLIS, MN--(Marketwire - November 06, 2008) - Virogen, Inc. (PINKSHEETS: VRGI), the developer and patent holder of a revolutionary vaccine to combat Newcastle disease, a deadly disease that kills chickens worldwide, reports that it has received purchase orders totaling $400,000 from its Asian and Middle Eastern distributors. This is truly a milestone for Virogen taking the company from its longstanding R&D phase to become a fully functional commercial enterprise. As anticipated, this purchase order follows shortly after receipt of VRGI's European Union (EU) manufacturing approval and licensing.
//-->